Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCC Cyclacel Pharmaceuticals	$8.23 +5.2%	$8.07	$3.08 ▼ $597.60	$18.44M	0.15	198,937 shs	96,729 shs
HOTH Hoth Therapeutics	$1.16 -4.1%	$1.28	$0.65 ▼ $3.80	$15.38M	0.67	191,322 shs	122,414 shs
IXHL Incannex Healthcare	$0.66 +6.6%	$0.49	$0.08 ▼ $3.12	$19.40M	7.66	141.57 million shs	83.22 million shs
SPRB Spruce Biosciences	$7.00 -6.7%	$7.36	$0.06 ▼ $0.61	$3.93M	2.43	802,052 shs	786 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCC Cyclacel Pharmaceuticals	0.00%	+3.00%	-26.58%	-66.73%	-96.97%
HOTH Hoth Therapeutics	0.00%	-10.77%	-12.78%	+38.19%	+64.07%
IXHL Incannex Healthcare	0.00%	+12.07%	+12.65%	+225.91%	-62.56%
SPRB Spruce Biosciences	-6.67%	-14.63%	-15.15%	+33.72%	-80.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYCC Cyclacel Pharmaceuticals	1.1085 of 5 stars	0.0	4.0	2.7	2.5	0.0
HOTH Hoth Therapeutics	2.6306 of 5 stars	3.5	5.0	2.0	0.0	0.6
IXHL Incannex Healthcare	0.1212 of 5 stars	0.0	2.0	1.8	0.8	0.0
SPRB Spruce Biosciences	1.6486 of 5 stars	3.0	3.0	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
HOTH Hoth Therapeutics	3.00	Buy	$4.00	244.83% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
SPRB Spruce Biosciences	2.00	Hold	$131.25	1,775.00% Upside

Current Analyst Ratings Breakdown

Latest SPRB, CYCC, IXHL, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYCC Cyclacel Pharmaceuticals	$40K	460.88	N/A	N/A	($58.87) per share	-0.14
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
IXHL Incannex Healthcare	$10K	1,939.44	N/A	N/A	$0.18 per share	3.66
SPRB Spruce Biosciences	$4.91M	0.80	N/A	N/A	$1.88 per share	3.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-723.64%	-145.51%	11/10/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-114.32%	-105.92%	11/11/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$99.25	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	11/10/2025 (Estimated)

Latest SPRB, CYCC, IXHL, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYCC Cyclacel Pharmaceuticals	N/A	5.77	5.77
HOTH Hoth Therapeutics	N/A	27.54	27.54
IXHL Incannex Healthcare	N/A	2.12	2.12
SPRB Spruce Biosciences	0.01	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYCC Cyclacel Pharmaceuticals	23.58%
HOTH Hoth Therapeutics	7.08%
IXHL Incannex Healthcare	0.43%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
CYCC Cyclacel Pharmaceuticals	51.20%
HOTH Hoth Therapeutics	6.92%
IXHL Incannex Healthcare	15.49%
SPRB Spruce Biosciences	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYCC Cyclacel Pharmaceuticals	14	2.24 million	1.09 million	Optionable
HOTH Hoth Therapeutics	4	13.26 million	12.34 million	Not Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
SPRB Spruce Biosciences	20	562,000	37.54 million	Optionable

SPRB, CYCC, IXHL, and HOTH Headlines

Recent News About These Companies

Head to Head Contrast: Spruce Biosciences (NASDAQ:SPRB) & MusclePharm (OTCMKTS:MSLP)

August 24, 2025 | americanbankingnews.com

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 14, 2025 | businesswire.com

Spruce Biosciences to enact 1-for-75 reverse stock split

July 24, 2025 | msn.com

Spruce Biosciences Announces Reverse Stock Split

July 24, 2025 | finance.yahoo.com

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

July 22, 2025 | globenewswire.com

SPRB Spruce Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market

June 13, 2025 | msn.com

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

June 12, 2025 | finance.yahoo.com

Spruce Biosciences’ Compliance Plan Accepted by Nasdaq

June 12, 2025 | tipranks.com

Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks

May 7, 2025 | investing.com

Spruce Biosciences Inc Ordinary Shares

May 6, 2025 | morningstar.comM

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 6, 2025 | finance.yahoo.com

Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset

April 28, 2025 | biospace.comB

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

April 28, 2025 | fiercebiotech.comF

Spruce Biosciences (SPRB) Receives a Hold from RBC Capital

April 17, 2025 | markets.businessinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript

April 17, 2025 | insidermonkey.com

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

April 15, 2025 | standard-journal.comS

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug

April 15, 2025 | bizjournals.com

Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)

April 15, 2025 | seekingalpha.com

Spruce Biosciences reports delayed annual filing

April 3, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, CYCC, IXHL, and HOTH Company Descriptions

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.23 +0.41 (+5.24%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$8.02 -0.22 (-2.61%)

As of 08/29/2025 07:50 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Hoth Therapeutics NASDAQ:HOTH

$1.16 -0.05 (-4.13%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.18 +0.02 (+1.72%)

As of 08/29/2025 07:42 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Incannex Healthcare NASDAQ:IXHL

$0.66 +0.04 (+6.63%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.15%)

As of 08/29/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Spruce Biosciences NASDAQ:SPRB

$7.00 -0.50 (-6.67%)

As of 08/29/2025

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time